NYSE:VNRX VolitionRx 3/25/2024 Earnings Report $0.48 -0.01 (-1.54%) Closing price 03:59 PM EasternExtended Trading$0.48 0.00 (-0.83%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast VolitionRx EPS ResultsActual EPS-$0.11Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AVolitionRx Revenue ResultsActual Revenue$0.24 millionExpected Revenue$0.50 millionBeat/MissMissed by -$260.00 thousandYoY Revenue GrowthN/AVolitionRx Announcement DetailsQuarterDate3/25/2024TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany ProfileConference Call Audio Live Call not available Earnings Conference CallVolitionRx 00:00 / 00:00Speed:1x1.25x1.5x2xPowered by VolitionRx Earnings HeadlinesVolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar marketsApril 29 at 8:30 AM | prnewswire.comVolitionRx enters new sales agreement, terminates old oneApril 24, 2025 | investing.comHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.May 2, 2025 | Brownstone Research (Ad)VolitionRx initiated with a Buy at H.C. WainwrightApril 8, 2025 | markets.businessinsider.comHC Wainwright & Co. Initiates Coverage of VolitionRx (VNRX) with Buy RecommendationApril 8, 2025 | msn.comEarnings call transcript: VolitionRx revenue beats forecast in Q4 2024April 2, 2025 | investing.comSee More VolitionRx Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like VolitionRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on VolitionRx and other key companies, straight to your email. Email Address About VolitionRxVolitionRx (NYSE:VNRX), a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.View VolitionRx ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be CautiousMeta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2Palantir Earnings: 1 Bullish Signal and 1 Area of ConcernMicrosoft Crushes Earnings, What’s Next for MSFT Stock?Qualcomm's Earnings: 2 Reasons to Buy, 1 to Stay AwayAMD Stock Signals Strong Buy Ahead of EarningsAmazon's Earnings Will Make or Break the Stock's Comeback Upcoming Earnings Palantir Technologies (5/5/2025)Vertex Pharmaceuticals (5/5/2025)CRH (5/5/2025)Realty Income (5/5/2025)Williams Companies (5/5/2025)American Electric Power (5/6/2025)Advanced Micro Devices (5/6/2025)Marriott International (5/6/2025)Constellation Energy (5/6/2025)Arista Networks (5/6/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
